Literature DB >> 25770475

TNFα Regulates SIRT1 Cleavage during Ocular Autoimmune Disease.

Peter J Gardner1, Samia Yazid2, Colin J Chu3, David A Copland4, Peter Adamson5, Andrew D Dick6, Virginia L Calder7.   

Abstract

Elevated tumor necrosis factor (TNF) α levels are associated with chronic autoimmune diseases in which effects of TNFα on immune cells are multiple and complex. Analysis of uveitis in mice exhibiting severe autoimmune inflammation, resulting in a destructive subtotal loss of photoreceptors, revealed the presence of high plasma levels of TNFα and a significant population of CD4(+)TNFα(+) cells in the periphery and the eye at peak disease (TNFα(hi)). We have shown previously by pharmacological activation that the deacetylase Sirtuin 1 (SIRT1) has an anti-inflammatory role in a less severe, TNFα(lo) model of uveitis. We now show that SIRT1 activation fails to clinically suppress severe TNFα(hi) disease, whereas glucocorticoid treatment is successful. TNFα has been reported to mediate cleavage and inactivation of SIRT1 during inflammation, and at peak disease we observed both full-length and cleaved SIRT1 in draining lymph node cells. In vivo systemic TNFα blockade suppressed severe ocular disease and restricted SIRT1 cleavage in the periphery, maintaining full-length active SIRT1 protein. When combining a suboptimal TNFα blockade with SIRT1 activation, a synergistic suppression of severe disease compared with TNFα blockade alone occurred. Our data suggest a new role for TNFα in exacerbating the severity of autoimmune disease by regulating SIRT1 cleavage in draining lymph node effector cells. SIRT1 activation may be effective as an adjunctive treatment for inflammatory conditions not fully controlled by TNFα inhibitors.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25770475     DOI: 10.1016/j.ajpath.2015.01.017

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  6 in total

1.  Therapeutic Validation of GEF-H1 Using a De Novo Designed Inhibitor in Models of Retinal Disease.

Authors:  Clare Mills; Sandra A Hemkemeyer; Zerin Alimajstorovic; Chantelle Bowers; Malihe Eskandarpour; John Greenwood; Virginia Calder; A W Edith Chan; Paul J Gane; David L Selwood; Karl Matter; Maria S Balda
Journal:  Cells       Date:  2022-05-24       Impact factor: 7.666

Review 2.  The Role of Sirtuins in Cartilage Homeostasis and Osteoarthritis.

Authors:  Mona Dvir-Ginzberg; Ali Mobasheri; Ashok Kumar
Journal:  Curr Rheumatol Rep       Date:  2016-07       Impact factor: 4.592

Review 3.  The Role of Sirtuin-1 in Immune Response and Systemic Lupus Erythematosus.

Authors:  Yueqi Qiu; Xingyu Zhou; Yu Liu; Siqi Tan; Yaping Li
Journal:  Front Immunol       Date:  2021-04-26       Impact factor: 7.561

Review 4.  The Versatility of Sirtuin-1 in Endocrinology and Immunology.

Authors:  Fahmida Rasha; Brianyell McDaniel Mims; Isabel Castro-Piedras; Betsy J Barnes; Matthew B Grisham; Rakhshanda Layeequr Rahman; Kevin Pruitt
Journal:  Front Cell Dev Biol       Date:  2020-11-19

Review 5.  SIRT1: A Potential Therapeutic Target in Autoimmune Diseases.

Authors:  Pan Shen; Xuan Deng; Zhe Chen; Xin Ba; Kai Qin; Ying Huang; Yao Huang; Tingting Li; Jiahui Yan; Shenghao Tu
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

6.  Flow cytometric analysis of inflammatory and resident myeloid populations in mouse ocular inflammatory models.

Authors:  Sidath E Liyanage; Peter J Gardner; Joana Ribeiro; Enrico Cristante; Robert D Sampson; Ulrich F O Luhmann; Robin R Ali; James W Bainbridge
Journal:  Exp Eye Res       Date:  2016-08-18       Impact factor: 3.467

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.